Notice of AGM

Summary by AI ^BETAClose X

GSK plc has published its Notice of Annual General Meeting 2026, which will be distributed to shareholders shortly and held on Wednesday, May 6, 2026, at 2:30 pm at the London Marriott Hotel Grosvenor Square, with an option for shareholders to join electronically. The company has also submitted the 2026 AGM Notice, Proxy Form, and proposed changes to its Articles of Association to the FCA for inspection.

Disclaimer*

GSK PLC

25 March 2026

Issued: 25 March 2026, London UK

GSK plc Publication of Notice of Annual General Meeting 2026

The Company has today published on its website (www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/) the Notice of Annual General Meeting ('AGM') 2026 (the '2026 AGM Notice'), which will be distributed to shareholders shortly.

The Company's AGM will be held on Wednesday 6 May 2026 at 2.30pm at the London Marriott Hotel Grosvenor Square, Grosvenor Square, London, W1K 6JP and will also be broadcast live for shareholders to join electronically. Full details of how to join the meeting either in person or electronically are contained in the 2026 AGM Notice and AGM Guide.

In compliance with Listing Rule 6.4.1R of the UK Financial Conduct Authority's ('FCA') Listing Rules, the following documents will be submitted to the FCA and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism:

· 2026 AGM Notice

· Proxy Form for the AGM

· The Company's Articles of Association marked up to show proposed changes

V A Whyte

Company Secretary

25 March 2026

About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2025.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END